ALGN vs BMY: Which Stock Is the Better Buy?
Align Technology, Inc. and Bristol-Myers Squibb Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ALGN vs BMY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Align Technology, Inc. (ALGN) | Bristol-Myers Squibb Company (BMY) | |
|---|---|---|
| Market cap | $12.1B | $133.4B |
| Revenue (latest FY) | $4.03B | $48.19B |
| Net income (latest FY) | $410.35M | $7.05B |
| Revenue growth (5y CAGR) | 10.3% | 2.5% |
| Net margin | 10.2% | 14.6% |
| Return on equity | 10.1% | 38.2% |
| P/E ratio | 29.3 | 14.4 |
| Dividend yield | — | 3.9% |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ALGN vs BMY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ALGN's full financials → Open BMY's full financials →More comparisons
Frequently asked questions
Which is bigger, ALGN or BMY?
Bristol-Myers Squibb Company is larger by market capitalization — $133.4B versus $12.1B.
Which grows faster, ALGN or BMY?
Over the last five fiscal years, Align Technology, Inc. grew revenue faster — 10.3%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.